PHARMACEUTICAL PREPARATIONS FOR ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND OTHER ASSOCIATED DISORDERS
A pharmaceutical preparation for the treatment of attention deficit disorders combines a therapeutically effective amount of digestive enzymes, such as chymotrypsin, and medication used to treat attention deficit disorders, such as Ritalin®, Concert®, Adderall® and Strattera®. The preparation may be in the form of a tablet, capsule or time released formula in order to reduce the amount of pills per dosage. The pharmaceutical preparation ameliorates the symptoms of the attention deficit disorder. The preparation has a stabilizing matrix containing a solidified microcrystalline cellulose which captures and protects therapeutically effective amounts of digestive enzyme particles within the stabilizing matrix.
1 . A pharmaceutical preparation to treat attention deficit disorders in an individual comprising a therapeutically effective amount of a medication used to treat attention deficit disorders and a therapeutically effective amount of digestive enzymes.
2 . The pharmaceutical preparation of claim 1 , wherein the medication used to treat attention deficit disorders is selected from the group consisting of methylphenidate, methylphenidate HCl, amphetamine, amphetamine salts, atomoxetine HCl, and a combination thereof.
3 . The pharmaceutical preparation of claim 1 , wherein the digestive enzyme is selected from the group consisting of: amylase, lipase, protease, cellulase, bromelain, chymotrypsin, trypsin, carboxypeptidase, elastase, hydrolase, pancreatin, papaya, papain, and a combination thereof.
4 . The pharmaceutical preparation of claim 1 , wherein the enzymes are derived from a source selected from the group consisting of animal enzymes, plant enzymes, synthetic enzymes, and a combination thereof.
5 . The pharmaceutical preparation of claim 1 , wherein the amount of methylphenidate ranges from 1 mg to 30 mg.
6 . The pharmaceutical preparation of claim 1 , wherein the amount of methylphenidate HCL ranges from 2.5 to 32 mg.
7 . The pharmaceutical preparation of claim 1 , wherein the amount of amphetamine ranges from 3.1 mg to 18.8 mg.
8 . The pharmaceutical preparation of claim 1 , wherein the amount of atomoxetine HCl ranges from 5 mg to 100 mg.
9 . The pharmaceutical preparation of claim 1 , wherein the digestive enzyme is chymotrypsin.
10 . The pharmaceutical preparation of claim 1 wherein the preparation is manufactured using a technology selected from the group consisting of Prosolv technology, enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation, and a combination thereof.
11 . The pharmaceutical preparation of claim 1 , wherein the preparation is administered orally via a dosage formulation selected from the group consisting of: pills, tablets, capsules, microcapsules, mini-capsules, time released capsules, mini-tabs, sprinkles, and a combination thereof.
12 . The pharmaceutical preparation of claim 1 , wherein the preparation is resistant to degradation by an environmental factor selected from the group consisting of light, heat, humidity, association with an excipient, and a combination thereof.
13 . The pharmaceutical preparation of claim 12 wherein the excipient provides a matrix to capture and protect the product before delivery.
14 . The pharmaceutical preparation of claim 1 , wherein the individual taking the preparation is able to reduce the amount of ADHD medication taken.
15 . The pharmaceutical preparation of claim 1 , wherein primary and secondary symptoms of the attention deficit disorder are ameliorated.
16 . The pharmaceutical preparation of claim 1 wherein the primary symptoms of the attention deficit disorder are selected from the group consisting of lack of attention span, impulsiveness, hyperactivity, and a combination thereof.
17 . The pharmaceutical preparation of claim 1 wherein the primary symptoms of the attention deficit disorder are selected from the group consisting of such as an inability to digest protein, gastrointestinal disorders, decreased appetite, insomnia, and a combination thereof.
18 . A method for the manufacture of a pharmaceutical preparation by direct compression comprising the steps of:
forming an active blend by blending an intimate admixture of silicified microcrystalline cellulose and a therapeutic agent comprising one or more digestive enzymes and one or more medications used to treat attention deficit disorder;
forming a color blend by blending an intimate admixture of a plurality of pharmaceutically acceptable dyes and a silicified microcrystalline cellulose;
combining the active blend, the color blend and a disintegrant into a preblend;
adding a lubricant to the preblend to form a final blend; and
compressing the final blend to form the pharmaceutical preparation.
19 . The method of claim 18 , wherein the silicified microcrystalline cellulose is ProSolv SMCC.
20 . The method of claim 18 , wherein the silicified microcrystalline cellulose has a particle size of 40 to 90 micrometers.
21 . The method of claim 18 , wherein the disintegrant is selected from the group consisting of: sodium starch glycolate, pregelatinized starch, cellulose, and a combination thereof.
22 . The method of claim 22 , wherein the lubricant is selected from a group consisting of: magnesium stearate, calcium stearate, talc, stearic acid, and a combination thereof.